tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET), Solid Biosciences (SLDB) and Dice Therapeutics (DICE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adicet Bio (ACETResearch Report), Solid Biosciences (SLDBResearch Report) and Dice Therapeutics (DICEResearch Report) with bullish sentiments.

Adicet Bio (ACET)

In a report issued on August 11, Justin Zelin from BTIG maintained a Buy rating on Adicet Bio, with a price target of $34.00. The company’s shares closed last Monday at $15.34.

According to TipRanks.com, Zelin is a 1-star analyst with an average return of -1.7% and a 41.9% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Precision BioSciences, CASI Pharmaceuticals, and Poseida Therapeutics.

Adicet Bio has an analyst consensus of Strong Buy, with a price target consensus of $28.50, which is an 87.1% upside from current levels. In a report issued on August 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Solid Biosciences (SLDB)

In a report issued on August 11, Joseph Schwartz from SVB Securities reiterated a Buy rating on Solid Biosciences, with a price target of $12.00. The company’s shares closed last Monday at $0.83, close to its 52-week low of $0.42.

According to TipRanks.com, Schwartz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.1% and a 47.0% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Solid Biosciences with a $6.67 average price target, a 684.7% upside from current levels. In a report issued on August 11, Chardan Capital also reiterated a Buy rating on the stock with a $6.00 price target.

Dice Therapeutics (DICE)

In a report issued on August 12, Thomas Smith from SVB Securities reiterated a Buy rating on Dice Therapeutics, with a price target of $46.00. The company’s shares closed last Monday at $21.03.

According to TipRanks.com, Smith has 0 stars on 0-5 stars ranking scale with an average return of -7.9% and a 40.5% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Eledon Pharmaceuticals.

Dice Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $43.00, representing an 112.0% upside. In a report issued on August 12, H.C. Wainwright also maintained a Buy rating on the stock with a $40.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACET:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More